Spectral’s vision is to provide a personalized approach that will enable vastly improve outcomes for patients with septic shock. TSX: $EDT.TO
Toronto, Ontario
- Tweets 458
- Following 11
- Followers 110
- Likes 23
Pinned Tweet
New topline data from the Phase 3 TIGRIS trial show that the mortality benefit observed with PMX at 28 and 90 days persisted through 12 months.
Read the full announcement and topline results: spectraldx.com/spectral-medi…
$EDT.TO
2
64
These findings illustrate the consequences of sepsis across the continuum of care and reinforce the urgency of earlier recognition, better identification of its biological drivers, and more precise treatment strategies for patients at highest risk.
Ref: buff.ly/mGhlu91
2
29
These figures reinforce the urgency of improving early recognition, identifying the biological drivers of sepsis, and advancing more precise treatment strategies for patients at highest risk.
Read the updated AHRQ data: buff.ly/KzYXpMG
#SepsisAwarenessMonth
1
22
This World Sepsis Day, we join the global sepsis community in raising awareness of a condition that affects millions of people and families every year.
Learn more about World Sepsis Day and how you can support the global campaign:
buff.ly/hHQpEh6
#WSD2026 #Sepsis
1
35
Spectral Medical is pleased to provide an update following its in-person 100-Day Meeting with the U.S. Food and Drug Administration regarding the Premarket Approval application for Toraymyxin™ (PMX).
Read the full news release: spectraldx.com/spectral-medi…
2
79
This September, learn the signs, share the facts, and join us in driving the awareness needed to transform patient outcomes.
Explore Sepsis Alliance resources and discover more ways to get involved: sepsis.org/get-involved/seps…
34
Critical care nurses play a central role in sepsis recognition, treatment and research.
Join us for a nurse-led discussion and two days of expert perspectives and practical insights at the virtual Sepsis Alliance Sepsis Summit.
Registration is free: buff.ly/y9YOH6L
1
1
29
Join us in supporting Sepsis Alliance this September by sharing educational resources, getting involved in your community or taking part in the Sepsis Superhero Challenge.
Explore the many ways you can help: buff.ly/vXg7pqx
#SAM2026 #15YearsOfSAM
29
Spectral Medical reported Q2 2026 results, highlighted by submission and formal filing of its PMA application for PMX with the FDA.
The Company also advanced preparations for anticipated pre-approval inspections and potential U.S. commercialization.
👉spectraldx.com/spectral-medi…
1
35
John Kellum: Getting into the end zone pittmed.pitt.edu/news/john-k…
1
29
New expert consensus in Critical Care examines patient selection, EAA-guided decision-making and PMX-HA in endotoxic septic shock, highlighting how clinical context and biomarker insight may help identify patients for targeted therapy.
👉 buff.ly/DhQC9X8
#FOAMed
1
31
In sepsis, the host response can be both protective and harmful. A recent review examines how the same mechanisms that defend against infection may drive cellular and organ dysfunction when the response becomes overwhelmed.
buff.ly/7Zx0b5n
#MedEd #SepsisResearch
1
31
In the latest episode of Cappuccino with Claudio Ronco, Prof. Ronco and Spectral Medical CMO Dr. John Kellum discuss the TIGRIS trial, Bayesian methodology, and patient selection in endotoxic septic shock.
Don't miss the conversation: buff.ly/XiDnjeC
#CriticalCare
39
Under LPS-stimulated conditions, PMX preferentially adsorbed activated granulocytes and neutrophils and reduced the neutrophil-to-lymphocyte ratio. These findings are hypothesis-generating, and their clinical relevance remains to be determined. 👉 buff.ly/g9XGiG3
31
Sepsis is not one disease. A new Journal of Intensive Care review highlights biomarker-guided care, including EAA™-identified endotoxic septic shock and PMX hemoadsorption in selected patients, citing TIGRIS as part of the evolving evidence. buff.ly/6TQnSFP
#SepticShock
1
41
We’re proud to congratulate our Chief Medical Officer, Dr. John Kellum, on his induction as a Fellow of the National Academy of Inventors. His pioneering work in sepsis, acute kidney injury, biomarkers and precision-guided care continues to shape critical care medicine. #NAI
48
Following the FDA’s filing of Spectral’s PMA application for PMX, supported by positive TIGRIS results, Dr. John Kellum highlights the need for targeted approaches in endotoxic septic shock. Read the full release 👉buff.ly/DuZxd0I
#ClinicalTrials #CriticalCareMedicine
39
Achieving macrovascular targets does not necessarily guarantee cellular resuscitation, a phenomenon often described as loss of hemodynamic coherence in septic shock.
👉 buff.ly/m9Uzp0O
#FOAMed #CriticalCare
1
31
The U.S. FDA has accepted Spectral’s PMA application for PMX. The application is supported by the Phase 3 TIGRIS trial, which met its primary endpoint and demonstrated sustained survival benefit through 12 months.
👉 buff.ly/0t63AsE
#Sepsis #SepticShock #CriticalCare
1
5
75
New mechanistic research in The International Journal of Artificial Organs explored the preferential removal of activated CD11b+ neutrophils and granulocytes by PMX hemoperfusion columns under inflammatory stimulation conditions.
1
1
30
The authors describe the findings as hypothesis-generating and supportive of ongoing investigation into potential immunomodulatory effects beyond endotoxin adsorption. Read the full publication: buff.ly/J8S9RAl
1
13